Decisions / 4860
final resolution2021-06-03active

Arzneimittel-Richtlinie/Anlage XII: Sebelipase alfa (Neubewertung nach Fristablauf: Mangel an lysosomaler saurer Lipase)

Open official decision page ↗

G-BA source · retrieved 2026-08-05

Structured conclusion

Final result by patient group

2 source-verified result

Patient group a

Patienten mit bereits im Säuglingsalter (< 6 Monate) rasch fortschreitendem LAL-Mangel:

Hint of non quantifiable added benefit

Comparator

Open official result PDF ↗

Patient group b

Patienten mit LAL-Mangel (nicht bereits im Säuglingsalter (< 6 Monate) rasch fortschreitend)

Hint of non quantifiable added benefit

Comparator

Open official result PDF ↗

Decision orientation

What the G-BA did

5 cited claims

Each claim links to the official G-BA page or an exact PDF page range.

Official metadata

Decision date
2021-06-03
Effective
03.06.2021
Action type
final resolution
Committee
Arzneimittel

Case context

Listed normative targets

directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V

A listed target is not treated as a new directive version unless an official version source exists.

Official document package